临床试验/NCT00353808

NCT00353808终止2 期

An Open-Label Extension Trial Assessing The Safety And Tolerability Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN).

Pfizer1 个研究点分布在 1 个国家目标入组 112 人开始时间: 2006年7月最近更新: 2011年4月7日

适应症

干预措施

试验速览

阶段: 2 期
状态: 终止
发起方: Pfizer
入组人数: 112
试验地点: 1
主要终点: Vital signs

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to assess the long-term safety and tolerability of [S,S]-Reboxetine in patients with chronic pain following shingles. This is the extension study of Protocol A6061026.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients must have met the patient selection criteria for the preceding double-blind Protocol A6061026 and have completed the 16-week trial.
•Patients at screening must have a score of >/=40mm on the pain visual analogue scale.

排除标准

•Serious adverse event during the preceding double-blind Protocol A6061026 that was determined to be related to the trial medication by the Investigator.
•Patient treatment compliance was less than 80% in the preceding double-blind Protocol A6061026.

研究组 & 干预措施

s, s reboxetine

Experimental

干预措施: [S,S]-Reboxetine (Drug)

结局指标

主要结局

Vital signs

Physical examination

12-lead ECG

Hematology/Biochemistry

Adverse events

次要结局

Pain Visual Analogue Scale
Patient Global Impression of Change

研究者

发起方

Pfizer

申办方类型

Industry

研究点 (1)

Loading locations...

相似试验

终止

2 期

[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.Pain

NCT00348894Pfizer136

终止

3 期

Open Label Extension Study of [S,S]-Reboxetine in Patients With FibromyalgiaFibromyalgia

NCT00754221Pfizer390

终止

3 期

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With SchizophreniaSchizophrenia

NCT04109950Otsuka Pharmaceutical Development & Commercialization, Inc.463

已完成

3 期

A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With HypertensionHypertension

NCT00457626Novartis Pharmaceuticals66

终止

3 期

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)Primary Immune Thrombocytopenia

NCT04596995UCB Biopharma SRL43